Latest news in cancer
Inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer
On October 10, 2024, the FDA approved inavolisib (Itovebi) combined with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated,...
Neoadjuvant/adjuvant nivolumab is approved by the USFDA for resectable non-small cell lung cancer
On October 3, 2024, the Food and Drug Administration sanctioned nivolumab (Opdivo, Bristol Myers Squibb Company) in conjunction with platinum-doublet...
Selpercatinib is approved by the USFDA for medullary thyroid cancer with a RET mutation
On September 27, 2024, the FDA granted traditional approval to selpercatinib (Retevmo) for treating advanced or metastatic medullary thyroid cancer (MTC) with...
Latest therapies in the treatment of hematological malignancies
Introduction Hematological malignancies, such as leukemias, lymphomas, and multiple myeloma, are a heterogeneous group of cancers that arise in the bone...
Osimertinib is approved by the USFDA for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy
On September 25, 2024, the FDA approved osimertinib (Tagrisso) for adults with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) with...
Isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone is approved by the USFDA for newly diagnosed multiple myeloma
The FDA has licensed isatuximab-irfc in combination with bortezomib, lenalidomide, and dexamethasone (Isa-VRd) for patients with newly diagnosed multiple...
Amivantamab-vmjw with carboplatin and pemetrexed is approved by the USFDA for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations
The FDA has approved Amivantamab-vmjw in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with non-small cell lung...
Pembrolizumab with chemotherapy is approved by the USFDA for unresectable advanced or metastatic malignant pleural mesothelioma
The FDA approved pembrolizumab (Keytruda) in combination with chemotherapy for the treatment of unresectable, advanced, or metastatic malignant pleural...
Kisqali with an aromatase inhibitor and Kisqali Femara Co-Pack is approved by the USFDA for early high-risk breast cancer
The FDA has approved Kisqali (ribociclib) plus an aromatase inhibitor and the Kisqali-Femara Co-Pack for early, high-risk breast cancer. The approval extends...
Bridging The Gaps In CAR T Cell therapy
Chimeric Antigen Receptor (CAR) T-cell therapy has transformed the treatment of hematologic malignancies but is confronting hurdles in the context of solid...
Personalized T-Cell therapies in the treatment of hematological malignancies
CAR-T cell therapy is a novel immunotherapy where a patient's T-cells are engineered to identify and destroy cancer cells. This personalized medicine has...
Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment
CAR T cell therapy has transformed cancer treatment, especially in hematological malignancies. Treatment of solid tumors remains challenging due to their...
How to prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies?
CAR T-cell therapy revolutionized cancer therapy, offering incredible success in the management of B-cell malignancies, but it is associated with severe...
Donor T cells for CAR T cell therapy
Donor-derived (allogeneic) CAR T cell therapy provides a scalable, affordable substitute for patient-specific (autologous) treatment, offering "off-the-shelf"...
Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Experience from China
China has made significant strides in optimizing chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Key strategies include improving...
CAR T-cell therapies in China: A Journey of Rapid Growth and Promise
The field of cancer therapy has been transformed with the introduction of chimeric antigen receptor (CAR) T-cell therapies, particularly in the field of...
Atezolizumab and hyaluronidase-tqjs is approved by FDA for subcutaneous injection
On September 12, 2024, the Food and Drug Administration sanctioned atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous...
Limkato: Korea’s first CAR T Cell therapy
South Korea is making significant strides in **CAR T cell therapy**, highlighted by the approval of **Limkato**, the first domestically developed CAR T therapy...
TIL therapy for melanoma in China
Tumor-Infiltrating Lymphocyte (TIL) therapy represents a promising advancement in the treatment of melanoma, particularly in cases where traditional treatments...
CAR T Cell therapy for breast cancer in China
Chimeric Antigen Receptor T-cell, or CAR T-cell therapy, has been a revolutionary form of treatment against numerous types of cancers such as breast cancer. In...
CAR T Cell therapy for pancreatic cancer in China
Pancreatic cancer is an aggressive cancer that is hard to detect until late in its course, and hence, treatment is challenging. It originates in the pancreas,...
CAR T Cell Therapy for Glioblastoma in China: A Revolutionary Approach to Brain Tumor Treatment
GBM The glioblastoma multiforme (GBM) is considered the most aggressive and lethal type of brain tumor. Despite treatments that include surgery, radiation, and...
CAR T Cell Therapy for AML in China: A Game-Changer in Leukemia Treatment
Acute myeloid leukemia (AML) Acute Myeloid Leukemia (AML) is a critical and aggressive form of blood cancer that necessitates advanced treatment options for...
Comparison of CAR T Cell Therapy in China vs. Global Markets
CAR T-cell therapy is revolutionizing cancer therapy, but its development and commercialization progress significantly differently between China and global...
Gamma Delta T Cell Therapy in Malaysia: A Revolution in Cancer Treatment
Gamma Delta T Cell therapy is revolutionizing cancer treatment by harnessing the immune system's power. This innovative approach is gaining momentum in...
Gamma Delta T Cell Therapy in Singapore: A Revolutionary Approach for Late-Stage Cancer Treatment
Gamma Delta (GD) T Cell therapy is revolutionizing stage 4 cancer treatment, offering hope to metastatic cancer patients. At Singapore's National University...
Indian went to China for CAR T Cell therapy – Patient story
CAR T-cell therapy has emerged as a groundbreaking treatment for diffuse large B-cell lymphoma (DLBCL) in China, offering new hope for patients with relapsed...
Chen Yan Story – Cured of beta thalassemia using CRISPR gene therapy
CRISPR/Cas9 gene therapy offers a groundbreaking approach to treating beta-thalassemia, a genetic blood disorder caused by defective hemoglobin production....
Children with brain cancer have new experimental CAR T-cell therapy
Experimental CAR T-cell therapy is offering hope for children with deadly brain cancers like diffuse midline gliomas (DMG). This innovative treatment...
CAR T Cell Therapy in Shanghai, China: A Comprehensive Guide
CAR T Cell therapy is transforming cancer treatment, and Shanghai has become a global hub for this revolutionary procedure. With cutting-edge hospitals like...
CAR T-Cell therapy in Mumbai, India
CAR T-cell therapy, an advanced cancer treatment, is now available in Mumbai, offering hope to those suffering from some types of blood cancers. This therapy...
LungVax: Lung cancer vaccine
LungVax is an innovative lung cancer vaccine designed to stimulate the immune system to target and destroy cancer cells. It is engineered to enhance the body's...
Successful CRISPR Gene Therapies in Practice: Case Studies
Presenting real-world examples of CRISPR gene therapies that have been successfully implemented, highlighting patient outcomes and lessons...
Gamma Delta (γδ) T cells as a potential treatment for glioblastoma
Gamma Delta (γδ) T cells are emerging as a promising immunotherapy for glioblastoma, a highly aggressive brain tumor. These unique T cells exhibit innate and...
World-first lung cancer vaccine trials started in seven countries
The lung cancer vaccine clinical trial had been recently launched in seven countries, including the United States, Japan, and Spain, which could prove to be an...
Lazertinib with amivantamab-vmjw is approved by the USFDA for non-small lung cancer
August 2024: The Food and Drug Administration (FDA) has granted approval for the use of lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.